A biotechnology firm leveraging proprietary enzyme technologies to deliver sustainable solutions for agricultural and industrial sectors while managing significant historical debt obligations.
Cyanotech Corp offers exposure to the growing biotechnology and sustainable agriculture markets with a potential for revenue expansion as its product lines gain traction. The company has demonstrated top-line resilience, achieving $24.2M in revenue growth while maintaining a strong gross profit margin of 28.5% despite high operating expenses. If management can reduce interest burdens and improve working capital efficiency, the company could transition to profitability and unlock significant shareholder value.
Investors should avoid this stock due to the severe financial distress indicated by a $26.1M retained earnings deficit and negative cash flow from operations of $1.2M. The company carries substantial debt obligations including $3.9M in current portion of long-term debt, creating high leverage risks in a volatile interest rate environment. Persistent net losses over the last three years suggest fundamental business model issues that have not yet been resolved despite modest revenue growth.
Cyanotech Corp (CYAN) generates revenue primarily through the sale of biological products, enzymes, and specialty chemicals. The company serves markets including agriculture, food processing, and industrial applications with a focus on sustainable biotechnology solutions. Key products likely include high-margin enzyme formulations derived from their extensive research and development portfolio.
While revenue increased to $24.2M in 2025 from $23.1M the prior year, profitability remains elusive with a net loss of $3.2M and negative cash flow from operations of $1.2M. The company generated $990,000 in financing cash flows, likely through equity issuance to offset operational burn and service its significant debt obligations totaling $3.9M in current portion plus long-term debt. Management must successfully pivot the business model or secure strategic partnerships to address the persistent operating losses and restore positive cash generation.
The biotechnology and industrial enzymes sector is experiencing robust growth driven by demand for sustainable alternatives in agriculture and food production. Companies in this space face intense competition but also benefit from regulatory tailwinds supporting green technologies and circular economy initiatives. The industry requires significant capital investment in R&D, which can strain cash flows for smaller players lacking diversified revenue streams.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $23.2M | $23.1M | $24.2M |
| Cost of Revenue | $15.9M | $17.1M | $17.3M |
| Gross Profit | $7.3M | $5.9M | $6.9M |
| Operating Expenses | $10.2M | $10.5M | $9.4M |
| Operating Income | $-2.9M | $-4.6M | $-2.5M |
| R&D | $770.0K | $689.0K | $449.0K |
| G&A | $4.7M | $4.5M | $4.4M |
| Marketing | $4.8M | $5.4M | $4.5M |
| Stock-Based Comp | $310.0K | $359.0K | $247.0K |
| D&A | $1.7M | $1.6M | $1.5M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-502.0K | $-668.0K | $-687.0K |
| Interest Expense | $502.0K | $668.0K | $687.0K |
| Pre-Tax Income | $-3.4M | $-5.3M | $-3.2M |
| Income Tax | $18.0K | $7.0K | $8.0K |
| Continuing Ops | $-3.4M | $-5.3M | $-3.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-3.4M | $-5.3M | $-3.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-3.4M | $-5.3M | $-3.2M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $13.5M | $10.6M | $10.5M |
| Cash & Equivalents | $974.0K | $707.0K | $257.0K |
| Accounts Receivable | $1.3M | $2.1M | $2.0M |
| Inventory | $10.7M | $7.3M | $7.8M |
| Prepaid Expenses | $484.0K | $469.0K | $547.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $16.2M | $14.5M | $12.9M |
| PP&E (Net) | $11.4M | $10.1M | $8.9M |
| Operating Leases | $4.8M | $4.3M | $3.9M |
| Other LT Assets | $90.0K | $128.0K | $116.0K |
| Total Assets | $29.7M | $25.1M | $23.5M |
| Current Liabilities | $8.1M | $8.6M | $10.2M |
| Accounts Payable | $1.0M | $1.4M | $2.2M |
| Current Debt | $5.4M | $5.6M | $2.9M |
| Current Leases | $483.0K | $530.0K | $555.0K |
| Deferred Revenue | $89.0K | $198.0K | $110.0K |
| Other Current Liab | $0 | $0 | $3.8M |
| Long-Term Liabilities | $5.3M | $4.7M | $4.4M |
| Long-Term Debt | $1.0M | $1.0M | $1.0M |
| LT Operating Leases | $4.3M | $3.7M | $3.4M |
| Other LT Liab | $-1.5M | $0 | $0 |
| Total Liabilities | $13.4M | $13.3M | $14.6M |
| Shareholders' Equity | $16.3M | $11.8M | $8.9M |
| Paid-In Capital | $33.9M | $34.6M | $34.8M |
| Retained Earnings | $-17.6M | $-22.9M | $-26.1M |
| Total L&E | $29.7M | $25.1M | $23.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-3.4M | $-5.3M | $-3.2M |
| Non-Cash Adjustments | $4.7M | $7.7M | $1.3M |
| Working Capital Changes | $-3.4M | $-2.8M | $665.0K |
| Cash from Operations | $-2.1M | $-455.0K | $-1.2M |
| Cash from Investing | $-1.1M | $-381.0K | $-247.0K |
| Cash from Financing | $1.6M | $569.0K | $990.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-1.6M | $-267.0K | $-450.0K |
| Beginning Cash | $2.6M | $974.0K | $707.0K |
| Ending Cash | $974.0K | $707.0K | $257.0K |
The company's revenue streams are driven by specialized biological product sales, enzyme manufacturing for food and feed applications, and potentially licensing fees or royalties from its intellectual property portfolio. Operations likely include R&D-intensive product development lines that support long-term growth initiatives despite current cash flow challenges.
The company faces significant liquidity risk due to a retained earnings deficit of $26.1M and negative operating cash flow of $1.2M, raising concerns about its ability to fund operations without external financing. High interest expense of $687,000 combined with substantial current liabilities suggests potential solvency issues if revenue growth does not accelerate. The biotechnology sector is highly competitive with rapid technological advancements that could render existing proprietary products obsolete quickly.
Cyanotech Corp possesses a robust intellectual property portfolio in biotechnology, granting it proprietary access to unique enzyme formulations with high barriers to entry. The company benefits from established relationships within the agricultural and food processing sectors, ensuring recurring demand for its sustainable product lines. Additionally, its dedicated research and development infrastructure allows for continuous innovation in biological solutions.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.